$200 per test is pretty darn cheap to get a worker back to work, kids back to school and health workers safe in their workplace
$300M is chicken feed in the scheme of Covid-19 and the economic impact.
As well $1.5M covers less than 10% of the population so lets just say that $300M is a starting revenue for the distributor. if you take a test costing $100 that is pretty good margin.
It is not unimaginable that >50% of the population may be tested at some stage so we need circa $12 Million test kits and that is only if you test half of the population once.
That is some seriously big revenue. Does anyone think our current $10M MC is going to last. Clearly will be in the spotlight of bigger Pharma.
Lets say an opening price of well above the recent cap raise. I'd speculate circa 40c plus post suspension lifting.
- Forums
- ASX - By Stock
- AN1
- Cellmid + COVID-19
Cellmid + COVID-19, page-27
-
- There are more pages in this discussion • 112 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable